PRESS-RELEASE ·Filed Jul 2, 2026
Press release · Contract
Actionable Insight • Neutral
This is a minor operational update with no immediate stock-moving catalyst. Monitor for future IND filing and clinical data readouts.
Final — all horizons settled through T+60d
VRXA ▼ -30.88% at T+60d
NEUTRAL call -30.88% · α vs SPY -33.89% · entry $2.04 → $1.41
T+1d
+7.35%
call +7.35% · α +6.48%
$2.19
settled 4mo ago
T+5d
+21.57%
call +21.57% · α +20.64%
$2.48
settled 4mo ago
T+20d
-3.92%
call -3.92% · α -3.51%
$1.96
settled 3mo ago
T+60d
-30.88%
call -30.88% · α -33.89%
$1.41
settled 29d ago
Price Chart
Loading chart...
Executive Summary
VERAXA Biotech announced the initiation of cell line development for its lead BiTAC-TCE program with ATUM, a critical but routine preclinical step toward IND-enabling activities. No financial terms or material milestones were disclosed.
Key Facts
- VERAXA engaged ATUM for cell line development of its lead BiTAC-TCE candidate using Leap-In Transposase technology.
- The collaboration supports stable clonal cell line generation for CMC development and nonclinical studies.
- ATUM's technology has supported over 50 IND submissions.
- No financial terms of the agreement were disclosed.
Financial Impact
No financial impact disclosed; preclinical milestone with no revenue or cost details.
Risk Factors
- Cell line development may encounter delays or technical challenges.
- BiTAC-TCE platform remains preclinical with no human efficacy or safety data.
- Company has limited cash runway; no financing details provided.
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3321216 |
16 reports for VRXA
100% Hit rate @ T+20 Went positive at some point 5 of 5 best @ T+60▲ +71.84%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | 6-K | $1.11 | awaiting T+20 | — | $0.9800 (−11.71%) |
Sep 4, 2026 7w ago | 6-K | $1.76 $1.13 | ▼ −35.80% | ▼ −36.40% | $0.9800 (−44.32%) |
Sep 4, 2026 7w ago | Press Release | $1.76 $1.13 | ▼ −35.80% | ▼ −36.40% | $0.9800 (−44.32%) |
Aug 24, 2026 9w ago | 6-K | $1.78 $1.46 | ▼ −17.98% | ▼ −17.99% | $0.9800 (−44.94%) |
Aug 10, 2026 11w ago | EFFECT | $1.85 $1.60 | ▲ +13.51% | ▲ +12.60% | $0.9800 (+47.03%) |
Aug 7, 2026 11w ago | EFFECT | $1.99 $1.76 | ▲ +11.56% | ▲ +11.16% | $0.9800 (+50.75%) |
Jul 31, 2026 12w ago | F-1 | $1.83 $1.35 | ▲ +26.23% | ▲ +27.47% | $0.9800 (+46.45%) |
Jul 31, 2026 12w ago | F-1 | $1.83 $1.35 | ▲ +26.23% | ▲ +27.47% | $0.9800 (+46.45%) |
Jul 27, 2026 13w ago | 6-K | $1.98 $1.73 | ▼ −12.63% | ▼ −16.01% | $0.9800 (−50.51%) |
Jul 27, 2026 13w ago | 6-K | $2.01 $1.78 | ▼ −11.44% | ▼ −14.74% | $0.9800 (−51.24%) |
Showing 10 of 16
US Market Status
Market Closed — Opens in 3h 56m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers